Scholar Rock Holding Corporation

NASDAQ:SRRK

Biotechnology

Healthcare
$48.00 +1.03%

+$0.49 today

Market cap
$5.86B
Beta
0.69
P/E (TTM)
-14.8
EPS (TTM)
-$3.21
52W Low $27.07High $52.19

Volume 2.77M

Average 1.46M

SRRK Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Scholar Rock Holding CorporationNASDAQ: SRRK

Other Income / Expenses · Q3 FY2026 · quarter ended Sep 2026

Other income / expenses turns negative

Q3 FY2026 other income / expenses was -$1.18M, compared with $1.33M a year earlier. Trailing-twelve-month other income / expenses was -$4.74M.

Context

  • Other income / expenses increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other income / expenses holds near -$1.18M or moves back toward the trailing-twelve-month quarterly average of -$1.18M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$1.18M-18.4% QoQ
Last fiscal yearDec 2025
$6.71M+16.4% YoY
LTMSep 2026
-$4.74M-154.6% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-188.6%——
1 year+16.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
6.71M USD
Year-over-year change
+16.4%

Other Income / Expenses vs competitors

How SRRK compares with its peers on the latest reported figures

  • SRRK's LTM Sep 2026 other income / expenses of -$4.74M is the 9th highest of the 11 companies compared; the peer median is $19.58M.
  • Its year-over-year change of -154.6% is the 10th highest of 11, against a peer median of +13.5%.
  • Other income / expenses amounts to 830.9% of revenue for SRRK, versus a peer median of 22.8%.
SRRK Competitors Peer median
Other Income / Expenses for SRRK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EWTXEdgewise Therapeutics, Inc.LTM Sep 2026$1.38B +5729.5%+80.5%—
BEAMBeam Therapeutics Inc.LTM Jun 2026$292.6M +517.4%+79.2%187.5%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$65.43M +239.3%—3.0%
XENEXenon Pharmaceuticals Inc.LTM Sep 2026$35.81M +15.2%+93.5%—
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$21.61M +11.8%-76.4%2.3%
DYNDyne Therapeutics, Inc.LTM Jun 2026$17.55M -37.4%+97.2%—
STOKStoke Therapeutics, Inc.LTM Mar 2026$14.2M +6.7%+60.9%44.3%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$11.51M +295.2%—57.5%
SRRKScholar Rock Holding CorporationLTM Sep 2026-$4.74M -154.6%—830.9%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026-$162.69M -29.8%—22.8%
PTCTPTC Therapeutics, Inc.LTM Jun 2026-$183.33M -250.6%—18.2%
Peer median (excluding SRRK) $19.58M+13.5%+79.8%22.8%

Competitors are the stored peer set for SRRK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.82M33.19M000
Cost of Revenue108.47M123.04M2.84M1.94M208.44M
Gross Profit(89.65M)(89.85M)(2.84M)(1.94M)(208.44M)
Gross Margin-476.5%-270.7%———
Research & Development108.47M124.44M119.06M182.61M208.44M
Selling, General & Admin40.27M42.62M49.4M67.5M176.21M
Operating Expenses40.27M44.52M168.45M250.12M176.21M
Depreciation & Amortization2.63M2.99M2.84M1.94M1.66M
EBITDA(129.17M)(129.48M)(162.95M)(237.52M)(369.39M)
EBITDA Margin-686.5%-390.1%———
Operating Income(129.92M)(134.37M)(171.3M)(252.05M)(384.65M)
Operating Margin-690.5%-404.8%———
Interest Income00012.68M13.9M
Interest Expense0006.84M6.89M
Other Income / Expenses(1.88M)(132K)5.51M5.76M6.71M
Income Before Tax(131.8M)(134.5M)(165.79M)(246.29M)(377.94M)
Pre-Tax Margin-700.5%-405.2%———
Income Tax Expense00000
Net Income(131.8M)(134.5M)(165.79M)(246.29M)(377.94M)
Net Margin-700.5%-405.2%———
EPS (Basic)(3.59)(2.21)(1.99)(2.47)(3.29)
EPS (Diluted)(3.59)(2.21)(1.99)(2.47)(3.29)
Weighted Avg Shares36.71M59.61M75.98M99.84M114.7M
Weighted Avg Shares (Diluted)36.71M59.61M75.98M99.84M114.7M

Scholar Rock Holding Corporation

NASDAQ:SRRK

Intrinsic Alpha fair value

Locked

Current Price

$48.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.